July 2026 Monthly Content Release Notes Copied

07/30/20262026 ContentContent releasePhysician, Clinical, Admin, Billing

Lab Analytes & Panels

Summary

This release includes seven newly created panels, updates to four existing panels, and 31 newly created analytes.

Additions

  • % CD3-CD16-/+CD56 br/dim, %
  • % CD3-CD16+CD56 dim, %
  • % CD3-CD16-CD56 br %
  • Abs CD3-CD16-/+CD56 br/dim, cells/uL
  • Abs CD3-CD16+CD56 dim, cells/uL
  • Abs CD3-CD16-CD56 br, cells/uL
  • Alpha 2-macroglobulins, qn (NASH), mg/dL
  • ALT (SGOT) P5P (NASH), IU/L
  • ANC Calc, 10×3/uL
  • Apolipoprotein A-1 (NASH), mg/dL
  • AST (SGOT) P5P (NASH), IU/L
  • Bilirubin, total (NASH), mg/dL
  • diff toxins A&B/GDH AG
  • Chlamydia, gonococcus/genital mycoplasma profile, NAA urine panel
  • Cholesterol, total (NASH), mg/dL
  • GGT (NASH), IU/L
  • Glucose (NASH), mg/dL
  • Haptoglobin (NASH), mg/dL
  • High grade B Cell lymphoma cells analyzed
  • High grade B Cell lymphoma cells counted
  • High grade B Cell lymphoma director review
  • High grade B Cell lymphoma FISH result
  • High grade B Cell lymphoma interpretation
  • High grade B Cell lymphoma specimen type
  • HIV combo screen w/reflex
  • Labcorp plasma detect ID MRD, baseline panel
  • Labcorp plasma detect ID MRD, monitoring panel
  • Mitochondrial M2 Ab, U/mL
  • Mycoplasma genitalium, NAA, swab with reflex to macrolide resistance testing panel
  • NASH methodology
  • OncoDetect panel
  • Plasma detect genome MRD baseline panel
  • Plasma detect genome MRD monitoring panel
  • Prostate-specific antigen (PSA), free: total ratio reflex panel
  • Rickettsia species
  • Triglycerides (NASH), mg/dL
  • Vitamin E, mg/L
  • Vitamin K, ng/mL

Updates

  • CBC w/ auto diff
  • High-grade/Large B-Cell lymphoma FISH panel
  • NASH fibrosure panel
  • Natural killer cell functional assay panel

Medications

Additions

  • AZD0901 invest IV
  • IEV407 invest Oral
  • MEN2312 invest Oral
  • MO-03 invest Oral
  • NEOK001 invest IV
  • NXP900 invest Oral
  • Sonesitatug vedotin invest (AZD0901 invest IV)
  • Sunscreen SPF 30 Topical

Updates

Medications Updates
CHS-114 invest IV

 

 New Name available:

  • Tagmokitug invest (CHS-114 invest IV)
EIK1001 invest IV SIGs available:

  • 0 mL intravenously once
  • 100 mL intravenously once

SIG suppressed:

  • 0 mg/kg intravenously once

Form available:

  • blinded solution (also for Research)
IBI363 invest IV Updated Form:

  • 0 mg/kg intravenously once
  • 0.1 mg/kg intravenously once
  • 1 mg/kg intravenously once
  • 1.5 mg/kg intravenously once
  • 3 mg/kg intravenously once
ONC-392 invest IV New Alias available:

  • Gotistobart invest (ONC-392 invest IV)

SIG available:

  • 0 mg/m2 suppressed
Tafasitamab invest (MOR00208 invest IV) New Name:

  • Tafasitamab invest (INCA000585; MOR00208 invest IV)

New SIG available:

  • 0 mg intravenously once
  • 1,000 mg intravenously once
Teclistamab-cqyv Subcutaneous Dose Rounding available:

  • 0.1 mg
Telisotuzumab Adizutecan invest (ABBV-400 invest IV) New Form available:

  • 110 mg recon soln (also for Research)
Yuvafem (Estradiol Vaginal Tablet) SIG suppressed:

  • 10 mcg vaginally 2 times per week

Regimens

Additions

Dexamethasone CRS Supportive Care Addition

 Added IV dexamethasone PRN order and an oral dexamethasone prescription (“Take-Home” or “Pocket” dexamethasone) to the PRN CRS Medications section of all T-cell engaging bispecific regimens to standardize CRS management, improve patient safety, and streamline provider workflows.

Fosnetupitant-palonosetron (Akynzeo) IV Antiemetic Addition

Added fosnetupitant-palonosetron (Akynzeo) IV as an available antiemetic option to all moderate, moderate-high, and high emetic risk regimen templates where it was not previously included. This update expands access to appropriate antiemetic therapy options and streamlines provider ordering by reducing the need for manual regimen modifications.

Tocilizumab Prophylaxis Addition

 Added prophylactic tocilizumab orders to the Premedications section of applicable T-cell engaging multiple myeloma bispecific regimen templates to support CRS risk mitigation, enhance patient safety, and reduce manual ordering burden.

Regimen Name Diagnosis
Capecitabine D1-14 + Oxaliplatin (XELOX/CAPOX) (Q21D) + Panitumumab (Q14D) Q42D ​​Colon Cancer; Rectal Cancer​
Nivolumab (240 mg) D1,15 + Ipilimumab (1 mg/kg) C1D1,C2D15,C4D1 (Q28D) fb Nivolumab IV C5+ Maintenance Q28D ​​Esophageal Cancer ​; ​Gastric Cancer​
Ribociclib D1-21 + Anastrozole + Goserelin Q3M Breast Cancer
Ribociclib D1-21 + Anastrozole + Leuprolide Q3M Breast Cancer
Ribociclib D1-21 + Letrozole + Goserelin Q3M Breast Cancer
Ribociclib D1-21 + Letrozole + Leuprolide Q3M Breast Cancer
Tecartus (Brexucabtagene Autoleucel IV) ​​Lymphoma, Non-Hodgkin (NHL) ​; ​Leukemia, Acute Lymphocytic (ALL)​
Vepdegestrant + Goserelin Q28D Breast Cancer
Vepdegestrant + Leuprolide Q28D Breast Cancer
Vepdegestrant Q30D Breast Cancer
Vimseltinib Q28D All Problems

Updates

  • ​Anal Cancer
  • Appendix Cancer, Carcinoma
  • Bile Duct Cancer
  • Breast Cancer​
  • Cervical Cancer
  • Colon Cancer
  • Esophageal Cancer
  • Fallopian Tube Cancer
  • Gallbladder Cancer
  • Gastric Cancer
  • ​Head and Neck Cancer
  • ​Leukemia, Chronic Lymphocytic (CLL)​
  • Lung Cancer, Non-small Cell (NSCLC)
  • ​​Lung Cancer, Small Cell (SCLC)​
  • ​Lymphoma, Non-Hodgkin (NHL) ​
  • Multiple Myeloma (MM)​
  • Neuroendocrine Tumor, Carcinoid
  • Ovarian and Primary Peritoneal Cancer
  • Pancreatic Cancer
  • Pancreatic Cancer, Carcinoid/Neuroendocrine
  • Rectal Cancer

Renames

Previous Name New Name
Acalabrutinib + Rituximab IV Maintenance Q56D Acalabrutinib + Rituximab IV Maintenance Q28D
Capecitabine D1-15 + Oxaliplatin (XELOX/CAPOX) + Cetuximab D1,8,15 Q21D Capecitabine D1-14 + Oxaliplatin (XELOX/CAPOX) + Cetuximab D1,8,15 Q21D
Datopotamab deruxtecan-dlnk Q21D Datopotamab deruxtecan Q21D
Talquetamab-tgvs (Talvey) SQ + Teclistamab-cqyv (Tecvayli) SQ D1,4,7,15,22 fb D1,8,15,22 fb D1,15 Q28D Talquetamab (Talvey) SQ + Teclistamab (Tecvayli) SQ D1,4,7,15,22 fb D1,8,15,22 fb D1,15 Q28D

Removals

Regimen Name Diagnosis
Dacomitinib Q30D Lung Cancer, Non-small Cell (NSCLC)
Influenza Vaccines 2025-2026 All Problems

Billing

Summary

If your practice applied a practice-specific override at the dispensable level for the previous HCPCS code J9171, suppress the J9171 billing row and confirm that an MSH Oncology billing row is available for HCPCS code J9232. If incorrect codes appear, refresh the Charge Capture Report to update the display.

Additions

Medication Codes
Calcium Folinate Invest IV C9310 per 1 mg
Fosaprepitant IV J3490 per 150 mg
Gadoquatrane IV J3490 per 0.1 mL
Veligrotug-vvze J3590 per 10 mg

Therapeutic Interchange Management

Summary

Details about recent content updates for Therapeutic Interchange Management content groups can be found on the Ontada Guide Site.